undamentalytics Newsletter
Sign in

Arrowhead Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Arrowhead Pharmaceuticals, Inc. had total assets of $1.39bn and shareholders' equity of $466m. It held $227m in cash against $255m of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Sept 20152016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Cash and equivalents83191338185253022214418410811110322755
Receivables—00——000111010079
Total current assets107291551039168792653223854054166959511,671
Total assets1617371831321281041123505237106927661,1401,3852,112
Accounts payable111351243879336111828
Deferred revenue (current)—000035078191117410295
Total current liabilities35912162619129741147139105103195283
Long-term debt110——322————————
Total debt11100332—0000393255723
Shareholders' equity131027167110968196245462409399271185466466
Shares outstanding17m——55m60m70m75m89m96m102m104m106m107m124m136m141m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ARWR vs NRIXARWR vs RAREARWR vs MIRMARWR vs TARS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arrowhead Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arrowhead Pharmaceuticals, Inc.